CVRX
CVRx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 2
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Price Hits 52-week Low
Double Bottom
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CVRX
Cvrx, Inc.
A commercial-stage medical device company focused on innovative neuromodulation solutions for cardiovascular diseases
Healthcare Equipment and Supplies
--
06/30/2021
NASDAQ Stock Exchange
206
12-31
Common stock
9201 West Broadway Avenue, Suite 650, Minneapolis, MN 55445
--
CVRx, Inc., was incorporated in Delaware in August 2000. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Their proprietary platform technology, Barostim, is the first medical technology approved by the US Food and Drug Administration to use neuromodulation to improve symptoms in patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the walls of the carotid artery. Barostim provides Baroreflex activation therapy, which in turn triggers an autonomic nervous response to the heart. The therapy aims to restore the balance of the autonomic nervous system, thereby reducing the symptoms of arrhythmia.
Earnings Call
Q2/2025
Estimate EPS-0.52
Actual EPS-0.57
Estimate Revenue13.22M
Actual Revenue13.60M
Navigating Contradictions: Insights from the Sales Force Turnover and Strategic Outlook in Q2 2025
Aug 04,2025 08:01
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CVRX has released its 2025 Q3 earnings. EPS was reported at -0.49, versus the expected -0.5, beating expectations. The chart below visualizes how CVRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CVRX has released its 2025 Q3 earnings report, with revenue of 14.69M, reflecting a YoY change of 9.85%, and net profit of -12.87M, showing a YoY change of 1.75%. The Sankey diagram below clearly presents CVRX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
